{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:36Z","timestamp":1791410796049,"version":"4.3.3"},"reference-count":103,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104777","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:17:55Z","timestamp":1764263875000},"page":"104777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["External beam radiotherapy for prostatic cancers: 2025 update"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-5218","authenticated-orcid":false,"given":"Igor","family":"Latorzeff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz\u00e9e","family":"Camps-Mal\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pommiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0520","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104777_bib0525","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.canrad.2025.104777_bib0530","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.fjurol.2024.102717","article-title":"French Afu Cancer Committee guidelines\u00a0\u2013\u00a0update 2024\u20132026: prostate cancer\u00a0\u2013\u00a0diagnosis and management of localised disease","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104777_bib0535","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.canrad.2025.104777_bib0540","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0545","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9327","key":"10.1016\/j.canrad.2025.104777_bib0550","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.canrad.2025.104777_bib0555","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.purol.2022.07.148","article-title":"French Afu Cancer Committee guidelines\u00a0\u2013\u00a0update 2022\u20132024: prostate cancer\u00a0\u2013\u00a0diagnosis and management of localised disease","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"10162","key":"10.1016\/j.canrad.2025.104777_bib0560","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0565","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0570","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10336","key":"10.1016\/j.canrad.2025.104777_bib0575","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"10467","key":"10.1016\/j.canrad.2025.104777_bib0580","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0585","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0590","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canrad.2023.05.004","article-title":"Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer","volume":"28","author":"Latorzeff","year":"2024","journal-title":"Cancer Radiother"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0595","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2018.06.027","article-title":"Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group","volume":"129","author":"Lieng","year":"2018","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104777_bib0600","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers14081943","article-title":"Magnetic resonance-guided reirradiation for local recurrence within the prostate or in the prostate bed: one-year clinical results of a prospective registry study","volume":"14","author":"Michalet","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0605","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1 results from the G\u00e9tug-Afu 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"10231","key":"10.1016\/j.canrad.2025.104777_bib0610","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"6\u20137","key":"10.1016\/j.canrad.2025.104777_bib0615","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.canrad.2010.07.229","article-title":"Cancer de prostate\u00a0: doses et volumes cibles","volume":"14","author":"Hennequin","year":"2010","journal-title":"Cancer Radiother"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0620","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the Getug-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0625","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijrobp.2006.05.074","article-title":"Whole-pelvis, \u201cmini-pelvis,\u201d or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial","volume":"66","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol"},{"issue":"5\u20136","key":"10.1016\/j.canrad.2025.104777_bib0630","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.canrad.2013.07.133","article-title":"Radioth\u00e9rapie pelvienne des cancers de la prostate\u00a0: quelle place pour quels volumes\u00a0?","volume":"17","author":"Chapet","year":"2013","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0635","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2023.07.020","article-title":"Consensus delineation guidelines for pelvic lymph node radiation therapy of prostate cancer: on behalf of the francophone group of urological radiation therapy (GFRU)","volume":"118","author":"De Hertogh","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104777_bib0640","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.canrad.2025.104777_bib0645","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0650","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70\u00a0Gy versus 80\u00a0Gy in localized prostate cancer: 5-year results of G\u00e9tug 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol"},{"issue":"4_suppl.","key":"10.1016\/j.canrad.2025.104777_bib0655","doi-asserted-by":"crossref","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs. 70\u00a0Gy) combined with long-term androgen deprivation in high-risk prostate cancers: G\u00e9tug-Afu 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0660","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.canrad.2020.11.004","article-title":"Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa)","volume":"25","author":"Peyraga","year":"2021","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0665","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"7","key":"10.1016\/j.canrad.2025.104777_bib0670","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0675","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euros.2023.06.003","article-title":"A multicenter phase 2 study of ultrahypofractionated stereotactic boost after external beam radiotherapy in intermediate-risk prostate carcinoma: a very long-term analysis of the CKNO-PRO trial","volume":"54","author":"Pasquier","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0680","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"De Vries","year":"2020","journal-title":"Int J Radiat Oncol"},{"issue":"1086","key":"10.1016\/j.canrad.2025.104777_bib0685","doi-asserted-by":"crossref","first-page":"20170807","DOI":"10.1259\/bjr.20170807","article-title":"Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard","volume":"91","author":"Martin","year":"2018","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0690","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jamaoncol.2018.6752","article-title":"Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs. conventional radiotherapy: a phase 3 randomized clinical trial","volume":"5","author":"Bruner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.canrad.2025.104777_bib0695","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104777_bib0700","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.canrad.2025.104777_bib0705","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0710","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104777_bib0715","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.canrad.2024.04.004","article-title":"Tol\u00e9rance \u00e0 court et moyen terme d\u2019une radioth\u00e9rapie prostatique hypofractionn\u00e9e selon la technique du boost int\u00e9gr\u00e9","volume":"28","author":"Larrivi\u00e8re","year":"2024","journal-title":"Cancer Radiother"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0720","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.clon.2019.12.002","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localised prostate cancer: ready for prime time?","volume":"32","author":"Cheung","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0725","first-page":"100702","article-title":"Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer","volume":"44","author":"Masson","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0730","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0735","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.canrad.2025.104777_bib0740","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0745","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10196","key":"10.1016\/j.canrad.2025.104777_bib0750","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104777_bib0755","doi-asserted-by":"crossref","first-page":"110568","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0760","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cancers13040759","article-title":"Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review","volume":"13","author":"Foerster","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.canrad.2025.104777_bib0765","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ctrv.2015.10.005","article-title":"Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French genito-urinary group and the French association of urology (G\u00e9tug-Afu)","volume":"41","author":"Sargos","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0770","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0775","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group Consensus Panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0780","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0785","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.canrad.2025.104777_bib0790","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104777_bib0795","doi-asserted-by":"crossref","first-page":"666962","DOI":"10.3389\/fonc.2021.666962","article-title":"Late gastrointestinal tolerance after prostate radiotherapy: is the anal canal the culprit? A narrative critical review","volume":"11","author":"Sargos","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0800","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.prro.2024.05.009","article-title":"Urinary organs at risk for prostate cancer external beam radiation therapy: contouring guidelines on behalf of the francophone group of urological radiation therapy","volume":"14","author":"Le Gu\u00e9velou","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0805","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2023.12.037","article-title":"Urethra-sparing prostate cancer stereotactic body radiation therapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial","volume":"119","author":"Achard","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0810","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S1470-2045(16)00063-2","article-title":"Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy","volume":"17","author":"Lee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0815","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2022.12.008","article-title":"Long-term results of a phase 3 randomized prospective trial of erectile tissue-sparing intensity-modulated radiation therapy for men with clinically localized prostate cancer","volume":"115","author":"Zhang","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0820","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ijrobp.2006.06.010","article-title":"Use of benchmark dose\u2013volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer","volume":"66","author":"Luo","year":"2006","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0825","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2006.05.037","article-title":"Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer","volume":"66","author":"Wang-Chesebro","year":"2006","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0830","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0835","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semradonc.2007.09.007","article-title":"Intensity-modulated radiation therapy: supportive data for prostate cancer","volume":"18","author":"Cahlon","year":"2008","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0840","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ijrobp.2011.09.015","article-title":"A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment","volume":"83","author":"Quan","year":"2012","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0845","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","article-title":"Dose\u2013volume effects for normal tissues in external radiotherapy: pelvis","volume":"93","author":"Fiorino","year":"2009","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0850","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0855","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ijrobp.2018.08.015","article-title":"A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy","volume":"102","author":"Olsson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib0860","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canrad.2017.11.004","article-title":"Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French genito-urinary group (G\u00e9tug) recommendations","volume":"22","author":"Langrand-Escure","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104777_bib0865","doi-asserted-by":"crossref","first-page":"103661","DOI":"10.1016\/j.critrevonc.2022.103661","article-title":"Highly hypofractionated schedules for localized prostate cancer: recommendations of the G\u00e9tug radiation oncology group","volume":"173","author":"Lapierre","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104777_bib0870","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0875","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the G\u00e9tug","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0880","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0885","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0890","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaoncol.2022.7592","article-title":"Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial","volume":"9","author":"Mariados","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6\u20137","key":"10.1016\/j.canrad.2025.104777_bib0895","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.canrad.2017.07.016","article-title":"Radioth\u00e9rapie hypofractionn\u00e9e mod\u00e9r\u00e9e contre radioth\u00e9rapie st\u00e9r\u00e9otaxique avec injection d\u2019acide hyaluronique dans les cancers de la prostate de risque faible \u00e0 interm\u00e9diaire\u00a0: toxicit\u00e9 aigu\u00eb dans l\u2019\u00e9tude RPAH2","volume":"21","author":"Chapet","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104777_bib0900","doi-asserted-by":"crossref","first-page":"701998","DOI":"10.3389\/fonc.2021.701998","article-title":"Use of a biodegradable, contrast-filled rectal spacer balloon in intensity-modulated radiotherapy for intermediate-risk prostate cancer patients: dosimetric gains in the BioPro-RCMI-1505 study","volume":"11","author":"Latorzeff","year":"2021","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.canrad.2025.104777_bib0905","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.purol.2022.07.147","article-title":"French Afu Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2022\u20132024: prostate cancer\u00a0\u2013\u00a0Management of metastatic disease and castration resistance","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104777_bib0910","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"},{"issue":"10260","key":"10.1016\/j.canrad.2025.104777_bib0915","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.canrad.2025.104777_bib0920","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (G\u00e9tug-Afu 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0925","doi-asserted-by":"crossref","first-page":"110532","DOI":"10.1016\/j.radonc.2024.110532","article-title":"Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: an individual patient data analysis of randomized trials from ICECaP database","volume":"201","author":"Pommier","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0930","doi-asserted-by":"crossref","first-page":"775387","DOI":"10.3389\/fonc.2022.775387","article-title":"Targeting local recurrence after surgery with MRI imaging for prostate cancer in the setting of salvage radiation therapy","volume":"12","author":"Renard-Penna","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0935","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104777_bib0940","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","article-title":"LBA64 Duration of androgen suppression with postoperative radiotherapy (DADSPORT): a collaborative meta-analysis of aggregate data","volume":"33","author":"Burdett","year":"2022","journal-title":"Ann Oncol"},{"issue":"10260","key":"10.1016\/j.canrad.2025.104777_bib0945","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canrad.2025.104777_bib0950","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (G\u00e9tug-Afu 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0955","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijrobp.2022.09.011","article-title":"G\u00e9tug-Afu 22 phase II randomized trial evaluating outcomes of post-operative immediate salvage radiation therapy with or without ADT for patients with persistently elevated PSA level","volume":"114","author":"Latorzeff","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"10338","key":"10.1016\/j.canrad.2025.104777_bib0960","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"2_suppl.","key":"10.1016\/j.canrad.2025.104777_bib0965","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2016.34.2_suppl.3","article-title":"NRG Oncology\/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA","volume":"34","author":"Shipley","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10442","key":"10.1016\/j.canrad.2025.104777_bib0970","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0975","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104777_bib0980","doi-asserted-by":"crossref","first-page":"109544","DOI":"10.1016\/j.radonc.2023.109544","article-title":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","volume":"183","author":"Schmidt-Hegemann","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib0985","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2023.02.013","article-title":"Prostatectomy bed image-guided dose-escalated salvage radiotherapy (SPIDER): an international multicenter retrospective study","volume":"6","author":"Benziane-Ouaritini","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0990","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of hypofractionated vs. conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 phase 3 randomized clinical trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib0995","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","article-title":"Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047)","volume":"86","author":"Parker","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104777_bib1000","doi-asserted-by":"crossref","first-page":"110690","DOI":"10.1016\/j.radonc.2024.110690","article-title":"Post-prostatectomy radiation therapy: updated guidelines of the Australian and New Zealand Radiation Oncology Genitourinary Group (FROGG)","volume":"204","author":"Warrender-Sparkes","year":"2025","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib1005","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the francophone group of urological radiation therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib1010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2007.07.017","article-title":"Guidelines for target volume definition in postoperative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group","volume":"84","author":"Poortmans","year":"2007","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104777_bib1015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104777_bib1020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2007.04.068","article-title":"Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy","volume":"69","author":"Wiltshire","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104777_bib1025","first-page":"100638","article-title":"ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer","volume":"41","author":"Dal Pra","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104777_bib1030","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the francophone group of urological radiation therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"updated-by":[{"DOI":"10.1016\/j.canrad.2026.104800","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:18:34Z","timestamp":1768738714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":103,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001933"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104777","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External beam radiotherapy for prostatic cancers: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104777"}}